OncoMatch/Clinical Trials/NCT04925479
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Is NCT04925479 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Asciminib Pediatric formulation group and Asciminib Adult formulation group for myeloid leukemia, philadelphia positive.
Treatment: Asciminib Pediatric formulation group · Asciminib Adult formulation group — The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML in the pediatric population has the same pathogenesis, similar clinical characteristics and progression pattern as in adults.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: BCR e14a2, e13a2
Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of screening which are amenable to standardized RQ-PCR quantification.
Required: ABL1 e14a2, e13a2
Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of screening which are amenable to standardized RQ-PCR quantification.
Excluded: ABL1 T315I
Known presence of the T315I mutation prior to study entry
Excluded: ABL1 any mutation with known resistance to study treatment
BCR::ABL mutation with known resistance to study treatment any time prior to study entry
Disease stage
Required: Stage CHRONIC PHASE
Excluded: Stage SECOND CHRONIC PHASE AFTER PREVIOUS PROGRESSION TO AP/BC
Participants with Ph+ CML-CP
Prior therapy
Must have received: BCR-ABL inhibitor
Prior treatment with a minimum of one TKI
Cannot have received: hematopoietic stem cell transplantation
Previous treatment with a hematopoietic stem-cell transplantation
Lab requirements
Blood counts
< 15% blasts in peripheral blood and bone marrow; < 30% combined blasts plus promyelocytes in peripheral blood and bone marrow; < 20% basophils in the peripheral blood; Neutrophils ≥ 1.5 x 10^9/L (or WBC ≥ 3 x 10^9/L if neutrophils are not available) and platelet count ≥ 100 x 10^9/L
Kidney function
adequate renal function required
Liver function
adequate hepatic function required; history of acute or chronic liver disease excluded
Cardiac function
adequate cardiac function required; cardiac or cardiac repolarization abnormality excluded
Participants must have adequate renal, hepatic, pancreatic and cardiac function; see laboratory values at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Indiana UH Riley H for CIU · Indianapolis, Indiana
- Dana Farber Cancer Institute · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
- University of Mississippi Medical Center · Jackson, Mississippi
- Columbia University Medical Center New York Presbyterian · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify